Loading…
Harrow, Inc. is projected to rise to $54.20 by 2027, a +28% move from its current price of $42.48. HROW is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $41.37 | $42.50 | $43.67 | +0.06% |
| Jul 14 | $40.94 | $42.53 | $44.18 | +0.11% |
| Jul 15 | $40.61 | $42.55 | $44.59 | +0.17% |
| Jul 16 | $40.34 | $42.58 | $44.94 | +0.23% |
| Jul 17 | $40.11 | $42.60 | $45.25 | +0.28% |
| Jul 18 | $39.90 | $42.62 | $45.54 | +0.34% |
| Jul 19 | $39.71 | $42.65 | $45.80 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $39.71 | $42.65 | $45.80 | +0.39% |
| Week 2 | $38.70 | $42.82 | $47.36 | +0.79% |
| Week 3 | $37.98 | $42.98 | $48.64 | +1.19% |
| Week 4 | $37.41 | $43.15 | $49.78 | +1.59% |
| Week 5 | $36.93 | $43.32 | $50.82 | +1.99% |
| Week 6 | $36.52 | $43.50 | $51.81 | +2.39% |
| Week 7 | $36.15 | $43.67 | $52.75 | +2.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.
It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc.
and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Harrow, Inc. trades under the symbol HROW and is an eyecare pharmaceutical company. The current price is $44.93.
A major floor 36.0% below — a decisive break under it would weaken the trend.
The nearest floor, 22.6% below — buyers have tended to step in here.
The nearest ceiling, 8.6% above — a clean break opens room to run.
A major ceiling 26.6% above — clearing it would confirm fresh momentum.
Key HROW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HROW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.31 | Sell | $43.48 | Sell |
| MA 10 | $43.30 | Sell | $43.15 | Sell |
| MA 20 | $41.99 | Buy | $41.68 | Buy |
| MA 50 | $37.74 | Buy | $39.49 | Buy |
| MA 100 | $38.80 | Buy | $39.39 | Buy |
| MA 200 | $41.34 | Buy | $39.23 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.07 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 19.56 | Neutral |
| Williams %R (14) | -73.40 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -0.70 | Sell |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 26.60 | Neutral |
| TRIX (15) | 0.80 | Buy |
| Awesome (5,34) | 5.62 | Buy |
| Ultimate (7,14,28) | 51.37 | Neutral |
| Momentum (10) | 0.98 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 44.30 | Sell |
| ADX (14) | 26.55 | Buy |
| ATR (14) | 1.05 | Info |
The stock’s 30-day technical picture is bullish, with RSI14 at 70, and the price above the SMA50 of $37.41 and the SMA200 of $41.35, indicating upside momentum. The stock sits near resistance at $44.93, with a 30-day range of $37.56 to $53.75 and a support level at $32.86.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.03 | $42.48 | $60.46 | 0% | Neutral | |
| $43.19 | $54.20 | $71.92 | +28% | Bullish | |
| $53.00 | $68.36 | $94.10 | +61% | Bullish | |
| $65.23 | $86.07 | $121.91 | +103% | Bullish | |
| $74.58 | $100.42 | $145.71 | +136% | Bullish | |
| $79.56 | $109.10 | $161.67 | +157% | Bullish | |
| $80.91 | $112.87 | $170.43 | +166% | Bullish | |
| $89.69 | $127.13 | $195.28 | +199% | Bullish | |
| $100.56 | $144.73 | $225.83 | +241% | Bullish | |
| $120.78 | $176.37 | $279.25 | +315% | Bullish | |
| $151.02 | $235.58 | $396.55 | +455% | Bullish | |
| $351.68 | $614.47 | $1,130.87 | +13.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $29.03 | $42.48 | $49.87 | +0.00% |
| August 2026 | $36.28 | $42.82 | $51.88 | +0.79% |
| September 2026 | $37.63 | $44.72 | $54.78 | +4.44% |
| October 2026 | $37.69 | $45.05 | $55.70 | +0.75% |
| November 2026 | $38.02 | $45.67 | $56.91 | +1.38% |
| December 2026 | $39.92 | $48.18 | $60.46 | +5.49% |
Click any year to see its month-by-month HROW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Harrow, Inc.'s 2026 outlook centres on $42.48, within a $29.03 to $60.46 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, HROW could reach as high as $71.92, with a base case around $54.20 and support toward $43.19 — roughly +28% from $42.48. Momentum favours further upside here.
Expect HROW to range from $53.00 to $94.10 through 2028. The $68.36 average target implies a +61% move from current prices. That is up +26% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The HROW price prediction for 2029 points to an average of $86.07 (low $65.23, high $121.91) — a potential gain of +103% on today's $42.48. Momentum favours further upside here.
In 2030, HROW is projected to trade between $74.58 and $145.71, averaging $100.42 — a potential gain of +136% from today's $42.48. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Harrow, Inc.'s 2031 outlook centres on $109.10, within a $79.56 to $161.67 range. That is up +9% on the projected 2030 average. That marks a +157% change versus current levels. Momentum favours further upside here.
By 2032, HROW could reach as high as $170.43, with a base case around $112.87 and support toward $80.91 — roughly +166% from $42.48. Buyers look set to stay in control over this stretch.
Expect HROW to range from $89.69 to $195.28 through 2033. The $127.13 average target implies a +199% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The HROW price prediction for 2034 points to an average of $144.73 (low $100.56, high $225.83) — a potential gain of +241% on today's $42.48. Buyers look set to stay in control over this stretch.
In 2035, HROW is projected to trade between $120.78 and $279.25, averaging $176.37 — a potential gain of +315% from today's $42.48. That is up +22% on the projected 2034 average. Momentum favours further upside here.
Harrow, Inc.'s 2040 outlook centres on $235.58, within a $151.02 to $396.55 range. That is up +34% on the projected 2035 average. That marks a +455% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, HROW could reach as high as $1,130.87, with a base case around $614.47 and support toward $351.68 — roughly +13.5x from $42.48. Momentum favours further upside here.
Investing $1,000 in HROW today (≈ 23.54049 HROW) could be worth
$14,465.01
+$13,465.01 (+1347%) by 2050 · US Dollar
Based on the average projected HROW price of $614.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HROWwould be worth at today's price.
$1,000 invested in HROW on Jul 10, 2025 (≈ 31.877589 HROW) would be worth
$1,354.16
+$354.16 (+35.4%) today · 1.35× · US Dollar
Based on a HROW entry price of $31.37 vs. today's $42.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $42.74 | $993.92 | -0.6% |
| 1 month ago | $35.9 | $1,183.29 | +18.3% |
| 3 months ago | $35.93 | $1,182.3 | +18.2% |
| 6 months ago | $47.84 | $887.96 | -11.2% |
| 1 year ago | $31.37 | $1,354.16 | +35.4% |
| All time (5.0y) ago | $7.46 | $5,694.37 | +469.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HROW forecast.
Our base-case forecast reaches $85.00 around 2029.
Implied market cap at $85.00: $3.17B
The multi-year forecast shows ongoing upside potential. For 2026, min $29.03, avg $44.93, max $65.25 with a neutral sentiment. From 2027 onward, sentiment turns bullish and the avg price climbs to: 2027 $59.34 (ROI 32.1%), 2028 $77.32 (ROI 72.1%), 2029 $98.92 (ROI 120.2%), 2030 $115.62 (ROI 157.3%), 2031 $127.68 (ROI 184.2%), 2032 $134.17 (ROI 198.6%), 2033 $152.30 (ROI 239%), 2034 $177.82 (ROI 295.8%), 2035 $218.51 (ROI 386.3%).
The bullish path continues to 2040 with avg $300.70 (ROI 569.3%) and to 2050 with avg $807.65 (ROI 1697.6%). The max forecasts rise even more, reaching $1,490.54 in 2050. These are estimates and not guarantees; uncertainty remains in any long-horizon outlook.
Tap a question to reveal the answer.
Avg $115.62; min $85.75; max $168.05; ROI 157.3%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with increasing averages: 2027 avg $59.34 (ROI 32.1%), 2030 avg $115.62 (ROI 157.3%), 2050 avg $807.65 (ROI 1697.6%).
Yes — the 2026 forecast lists a max of $65.25, while the current price is $44.93.
30-day range is $37.56 to $53.75.
Avg $807.65; min $460.42; max $1,490.54; ROI 1697.6%; sentiment BULLISH.
Harrow, Inc. Community Discussion
0Share your Harrow, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.